Onconova to present clinical trials update on ON 01910.Na at American Society of Hematology Meeting

December 03, 2010

NEWTOWN, PA and PRINCETON, NJ Dec. 3, 2010 / PRNewswire-FirstCall / Onconova Therapeutics announces its late-stage anticancer agent, Estybon® (ON 01910.Na), will be featured in three presentations at the 52nd American Society of Hematology (ASH) Annual Meeting in Orlando, FL, December 4-7, 2010.

Principal investigators at four centers, Dr. Lewis Silverman (Mount Sinai Medical Center), Dr. Azra Raza (Columbia University Medical Center), Dr. Elaine Sloand (NHLBI), and Dr. Peter Greenberg (Stanford University Medical Center) report that in 48 higher risk patients with MDS or AML (who failed or became resistant to previous drug treatments), when treated with ON 01910.Na showed increases in overall survival, which correlated with bone marrow blast responses. The most dramatic improvement in overall survival was seen in 19 patients who also showed either bone marrow complete response (CR) or initial >50% decrease in blast cells (Abstract #3998). Dr. Greenberg's team reports encouraging efficacy and drug tolerance results in a Phase II trial with patients who had all failed the standard hypomethylating agent treatments (Abstract #4010). Dr. Silverman and colleagues have observed 50% responders in a Phase I study (Abstract #2944).

Estybon® (ON 01910.Na) is a small molecule, targeted therapeutic with a broad spectrum of activity. It has been tested in patients with solid tumors, myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) at major centers in the U.S. and abroad. MDS and AML are blood disorders widely recognized as difficult to manage, with limited therapeutic options for patients, especially those with drug-resistant disease. The presentations will describe the latest results on activity and safety of Estybon® (ON 01910.Na) in MDS and AML patients treated in on-going Phase I and Phase II clinical trials.

These studies are a part of comprehensive evaluation of the safety and activity of Estybon® (ON 01910.Na). To date, nearly 300 cancer patients have been treated in Phase I and Phase II trials, including more than 70 patients with MDS or AML. These studies have lead to a multi-site Phase III pivotal trial under a Special Protocol Assessment (SPA) from the U.S. FDA. This trial is being supported by an award from the Therapeutics Acceleration Program (TAP) of the Leukemia and Lymphoma Society (LLS).

"We continue to make meaningful progress in our MDS program, and information to be presented at the ASH meeting reflects the breadth of data becoming available for ON 01910.Na in MDS patients," said Francois Wilhelm, MD, PhD, Senior Vice President and Chief Medical Officer of Onconova. "We are committed to the rapid development of this promising agent for MDS patients by conducting a multi-site trial in the United States and France," Dr. Wilhelm added.

Another presentation will highlight the mechanism of action and activity in nonclinical models of mantle cell lymphoma (MCL) of ON 013105, a novel Onconova agent directed to controlling Cyclin D1 in cancer cells (Abstract #771). ON 013105 alone or in combination with rituximab induced dramatic reduction of MCL tumor volumes in mouse xenograft models, suggesting that ON 013105 alone or in combination may be a potent therapeutic agent against MCL. ON 013105 is currently in Phase I clinical safety studies in lymphoma patients.
-end-
About ESTYBON

Estybon® (ON 01910.Na), is a small molecule inhibitor of critical pathways important in the growth and proliferation of cancer cells. Extensive Phase I and Phase II studies with Estybon® have been conducted in patients with solid tumors and hematological cancers, including MDS and AML, where more than 70 patients have been enrolled in studies conducted at four leading institutions in the U.S. FDA has granted Orphan Drug Designation for the use of Estybon® in MDS. A U.S. Patent covering ON 01910.Na issued in October 2009 and international patent coverage is expected.

About Onconova Therapeutics, Inc.

Onconova, based in Newtown, PA and Princeton, NJ, discovers and develops novel small molecule therapeutics with fully differentiated targets involved in signal transduction, cell-cycle, and DNA repair. These candidates are derived from a proprietary library of new chemical entities and non-ATP competitive chemotypes. In addition to Estybon® (ON 01910.Na) and ON 013105, Onconova is also developing Ex-RAD®, an injectable and oral radioprotectant. The oncology preclinical pipeline at Onconova includes inhibitors of Plk2, ALK, CDK, JAK, and Bcr-Abl pathways and a novel immunoconjugate platform for arming therapeutic antibodies. Currently, Onconova is conducting clinical trials at major centers in the U.S. and abroad for three product candidates. For additional information, please visit http://www.onconova.com.

Summary of ASH Presentations Relating to Estybon® (ON 01910.Na) and ON 013105

Sunday, December 5:
Session: Myelodysplastic Syndromes Poster II, Hall A3/A4 (Orange County Convention Center)

Poster Board # II-824
Abstract #2944
"Evaluation of ON 01910.Na in Patients with a Myelodysplastic Syndrome (MDS) or Acute
Myeloid Leukemia (AML) Relapsed or Refractory to Hypomethylating Agents: A Phase I Study"
Lewis R Silverman, Shyamala C. Navada, Rosalie Odchimar-Reissig, Vesna Najfeld, Takao Ohnuma, Francois Wilhelm, E. Premkumar Reddy, James F. Holland; Division of Hematology/Oncology, Mount Sinai School of Medicine, New York, NY; Mount Sinai School of Medicine, New York, NY; Onconova Therapeutics, Inc., Newtown, PA

Monday, December 6:
Session: Myelodysplastic Syndromes Poster III, Hall A3/A4 (Orange County Convention Center)

Poster Board # III-777
Abstract #3998
"Overall Survival in Patients with a Myelodysplastic Syndrome or Acute Myeloid Leukemia Treated With ON 01910.Na Correlates with Bone Marrow Blast Response"
Lewis R. Silverman, Azra Raza, Elaine Sloand, Peter L. Greenberg, Francois Wilhelm; Mount Sinai Medical Center, New York, NY, Columbia University Medical Center, New York, NY, National Heart, Lung and Blood Institute, Bethesda, MD, Stanford University Cancer Center, Stanford, CA, Onconova Therapeutics, Inc., Newtown, PA

Poster Board # III-789
Abstract #4010
"Treatment of Higher Risk Myelodysplastic Syndrome Patients Unresponsive to Hypomethylating Agents with ON 01910.Na"
Mahesh Seetharam, Mai Tran, Alice C. Fan, Liwen Xu, John P. Renschler, Dean W. Felsher, Kunju Sridhar, Francois Wilhelm, Peter L. Greenberg; Departments of Medicine (Hematology) and Medicine (Oncology), Stanford University Cancer Center, Stanford, CA;, Onconova Therapeutics Inc., Newtown, PA

Session: Lymphoma/Pre-Clinical/Chemotherapy and Biologic Agents: Preclinical Advances in Mantle Cell Lymphoma (Oral Presentations); Session Time 4:30 - 6:00 PM; Room 308 (Orange County Convention Center)

Presentation Time: 5:00 PM
Abstract #771
"Synergistic Effects of a Novel Water-soluble Small Molecule, ON 013105, and Rituximab on Mantle Cell Lymphoma In vitro and In vivo"
Anil Prasad, Ashutosh Shrivastava, Ramana MV Reddy, Amanda Gillum, E. Premkumar Kumar Reddy, Jerome Groopman: Division of Experimental Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Department of Oncological Sciences, Mount Sinai School of Medicine, New York, NY, Onconova Therapeutics, Inc., Newtown, PA

PR on Call

Related Myelodysplastic Syndromes Articles from Brightsurf:

Effects of acute and chronic graft-versus-myelodysplastic syndrome on long-term outcomes following a
A research group led by Assistant Professor Takaaki Konuma in the Department of Hematology/Oncology, the Hospital of the Institute of Medical Science, the University of Tokyo (IMSUT Hospital) has demonstrated a graft-versus-tumor (GVT) effect of a previously unknown/novel allogeneic hematopoietic cell transplantation in MDS patients.

RTL1 gene a likely culprit behind temple and Kagami-Ogata syndromes
Researchers from Tokyo Medical and Dental University (TMDU) have found that Rtl1, which is a mouse ortholog of the human RTL1 gene, appears to be the major gene responsible for muscle and placental defects in models of Temple and Kagami-Ogata syndromes, which are serious genetic conditions.

Identified gene mutations impact on the severity of a type of hematologic cancer
Researchers from Josep Carreras Leukemia Research Institute participate in an international study that confirms for the first time that mutation of the two TP53 gene's copies is associated with a worse prognosis in myelodysplastic syndromes, a group of blood cancers a more frequent in elderly population.

Identified the genetic landscape of myelodysplastic/myeloproliferative neoplasms
Researchers from the MDS Group of the Josep Carreras Leukaemia Research Institute and the Munich Leukemia Laboratory map the mutations that can ease and accelerate the diagnosis of Myelodysplastic/Myeloproliferative Neoplasms rare malignancies.

Merits of revascularisation and medical treatment for chronic coronary syndromes
There are two treatment goals for patients with chronic coronary syndromes: reducing the risk of hard outcomes (i.e., death, myocardial infarction) and improving health outcomes (i.e. angina symptoms, quality of life).

New treatment target verification for myelodysplastic syndrome
A Japanese research group analyzed the pathophysiology of myelodysplastic syndrome (MDS), a blood cancer that presents often in the elderly, and found the presence of transcription factor RUNX3, thereby revealing a cancer growth function for what had been considered be a tumor suppressor.

Research revises classification of acute myeloid leukemia & myelodysplastic syndrome
Findings presented as a late-breaking abstract at the American Society of Hematology annual meeting by St.

A new facial analysis method detects genetic syndromes with high precision and specificity
Developed by Araceli Morales, Gemma Piella and Federico Sukno, members of the Department of Information and Communication Technologies, together with researchers from the University of Washington, which they present in a feature in the advanced online edition of Lecture Notes in Computer Science of Oct.

Published a clinical guide for the genomic diagnosis of Myelodysplastic Syndromes and Chronic Myelomonocytic leukaemia
A collective work between researchers from 8 research centres and hospitals in Spain, coordinated by Francesc Solé of the Josep Carreras Leukaemia Research Institute (IJC), and Esperanza Such, of the University and Polytechnic Hospital de la Fe describes the recommendations of use of the Next Generation genome Sequencing (NGS) in the diagnosis of Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML).

Pollution and noise reduction advised in ESC guidelines on chronic coronary syndromes
The detrimental impact of pollution and noise on patients with chronic coronary syndromes is highlighted for the first time in European Society of Cardiology (ESC) Guidelines published online today in European Heart Journal, and on the ESC website.

Read More: Myelodysplastic Syndromes News and Myelodysplastic Syndromes Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.